PLx Pharma Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
September 09 2021 - 6:50AM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform to provide more effective and safer products, with its
lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled
aspirin capsules (referred to together as “VAZALORE”), today
announced that Natasha Giordano, President and Chief Executive
Officer, and Rita O’Connor, Chief Financial Officer, will present
virtually at two upcoming healthcare conferences as follows:
Oppenheimer Fall Healthcare Life Sciences
& MedTech Summit: |
|
Date: |
Tuesday,
September 21, 2021 |
|
|
Time: |
2:55PM Eastern Time |
|
|
Webcast Link: |
https://wsw.com/webcast/oppenheimer16/plxp/2825452 |
|
|
2021 Cantor Global Healthcare
Conference: |
|
Date: |
Wednesday, September 29, 2021 |
|
|
Time: |
8:40AM Eastern Time |
|
|
Webcast Link: |
https://wsw.com/webcast/cantor12/plxp/2118760 |
|
|
The presentations will be webcast live at the aforementioned
times, and archived for 30 days thereafter, via the Company’s
website at www.plxpharma.com, under the ‘Investors Relations’
Section.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule that
provides patients with vascular disease and diabetic patients who
are candidates for aspirin therapy based on physician
recommendation, with fast, reliable and predictable platelet
inhibition as compared to enteric-coated aspirin. It also reduces
the risk of stomach erosions and ulcers, as compared to
immediate-release aspirin, common in an acute setting. To learn
more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma Inc. is a specialty pharmaceutical company focused on
its clinically-validated and patent-protected PLxGuard™ drug
delivery platform to provide more effective and safer products. The
PLxGuard drug delivery platform works by targeting the release of
active pharmaceutical ingredients to various portions of the
gastrointestinal (GI) tract. PLx believes this platform has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce the risk of stomach
erosions and ulcers associated with certain drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Contact Investor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024